达格列净对2型糖尿病合并慢性心力衰竭患者氧化应激及左心室肥厚的影响

Effect of dapagliflozin on oxidative stress and left ventricular hypertrophy in patients with type 2 diabetes mellitus and chronic heart failure

目的:探讨达格列净对2型糖尿病(T2DM)合并慢性心力衰竭(CHF)患者氧化应激及左心室肥厚的影响。方法:纳入2020年1月至10月我院收治的114例T2DM并CHF患者。采用随机数字表法将患者分为常规组(传统药物治疗)和达格列净组(在常规组的基础上增加达格列净口服治疗),每组57例。治疗6个月后,比较两组患者治疗前后左心室肥厚程度、氧化应激、左心室重构及血糖代谢指标。结果:6个月治疗结束后共失访15例,最终纳入99例患者,其中常规组47例,达格列净组52例。治疗6个月后,与常规组比较,达格列净组超氧化物歧化酶(SOD)[(33.17±6.05)U/L比(37.43±6.22)U/L]水平显著升高(P<0.001);活性氧(ROS)[(613.63±36.50)U/ml比(597.12±39.85)U/ml]、左心室舒张末期容积指数(LVEDVI)[(49.31±2.58)ml/m^(2)比(47.60±2.53)ml/m^(2)]、左心室收缩末期容积指数(LVESVI)[(31.18±2.37)ml/m^(2)比(29.44±2.26)ml/m^(2)]、左心室心肌质量指数(LVMI)[(107.93±6.46)g/m^(2)比(104.85±6.19)g/m^(2)]、左心室肥厚发生率(19.15%比5.77%)及空腹血糖(FBG)[(6.33±1.56)mmol/L比(5.65±1.42)mmol/L]、餐后2h血糖(2hPG)[(7.35±1.11)mmol/L比(6.46±2.10)mmol/L]和糖化血红蛋白(HbA1c)[(7.30±1.41)%比(6.62±1.29)%]水平均显著降低(P<0.05或<0.01)。结论:2型糖尿病合并慢性心力衰竭患者在传统药物治疗的基础上联合达格列净治疗,可进一步改善血糖水平,并抑制氧化应激反应,延缓左心室重构进程,降低左心室肥厚发生率。

Objective:To explore effect of dapagliflozin on oxidative stress and left ventricular hypertrophy in patients with type 2 diabetes mellitus(T2DM)and chronic heart failure(CHF).Methods:A total of 114 T2DM+CHF patients treated in our hospital from January 2020 to October 2020 were included.They were divided into routine group(traditional medication)and dapagliflozin group(dapagliflozin oral therapy based on routine group)by random number table method,with 57 cases in each group.After 6-month treatment,left ventricular hypertrophy degree,indexes of oxidative stress,left ventricular remodeling and glucose metabolism were compared between two groups before and after treatment.Results:After 6-month treatment,15 cases were lost and 99 patients were finally included,including 47 patients in the routine group and 52 patients in the dapagliflozin group.After 6-month treatment,compared with routine group,there was significant rise in superoxide dismutase(SOD)level[(33.17±6.05)U/L vs.(37.43±6.22)U/L](P<0.001),and significant reductions in reactive oxygen species(ROS)[(613.63±36.50)U/ml vs.(597.12±39.85)U/ml],left ventricular end-diastolic volume index(LVEDVI)[(49.31±2.58)ml/m^(2) vs.(47.60±2.53)ml/m^(2)],left ventricular end-systolic volume index(LVESVI)[(31.18±2.37)ml/m^(2) vs.(29.44±2.26)ml/m^(2)],left ventricular mass index(LVMI)[(107.93±6.46)g/m^(2) vs.(104.85±6.19)g/m^(2)],incidence rate of left ventricular hypertrophy(19.15%vs.5.77%),levels of fasting blood glucose(FBG)[(6.33±1.56)mmol/L vs.(5.65±1.42)mmol/L],2h postprandial glucose(2hPG)[(7.35±1.11)mmol/L vs.(6.46±2.10)mmol/L]and glycosylated hemoglobin A1c(HbA1c)[(7.30±1.41)%vs.(6.62±1.29)%]in dapagliflozin group,P<0.05 or<0.01.Conclusion:Dapagliflozin on the basis of traditional medication can further improve blood glucose,inhibit oxidative stress,delay the process of left ventricular remodeling,and reduce the incidence of left ventricular hypertrophy in patients with type 2 diabetes mellitus and chronic heart failure.